Immune cell axis linked to tuberculosis treatment failure

Tuberculosis (TB) treatment usually follows predictable timelines, and sputum culture conversion (SCC) at 2 months is an important early sign that therapy is working. Yet some people do not show SCC at this milestone, and the immune changes behind that treatment non-response have been unclear. To investigate, a team led by corresponding author ZhenBo Wang examined blood immune cells from people with active TB and compared those who did or did not achieve SCC at 2 months. The researchers used single-cell RNA sequencing on peripheral blood mononuclear cells to look at each cell’s activity, allowing them to capture the full diversity and communication patterns among immune cells. By studying these individual immune cells and how they interact, the team aimed to find cellular features and signaling pathways that distinguish treatment responders from non-responders and to uncover potential biomarkers or targets that could explain why some patients fail to clear the infection on standard treatment timelines.

The study analyzed peripheral blood mononuclear cells from 8 TB patients, stratified by their 2-month SCC status, using single-cell RNA sequencing to map cell types and signaling. Key findings showed a marked expansion and terminal differentiation of non-classical monocytes in treatment non-responders; these monocytes carried signatures associated with higher TB progression risk. Functionally, these non-classical monocytes had reduced outgoing but enhanced incoming signaling, with IL-16 and TRAIL pathways highlighted as prominent routes of communication. The altered signaling patterns appeared to interact with CD4⁺ Tregs, which in non-responders intensified GALECTIN signaling toward CD8⁺ cytotoxic T cells and mature NK cells. NK cell subsets, especially mature NK c2, showed signs of terminal differentiation and increased inhibitory receptor expression, consistent with exhausted effector function. Together these observations outline a dysregulated “non-classical monocyte -Treg -cytotoxic lymphocyte” axis associated with TB treatment failure and point to candidate biomarkers and host-directed therapeutic targets.

These results suggest a form of immunodepression driven by specific blood immune cells in patients who do not convert their sputum cultures at 2 months. The expansion and altered signaling of non-classical monocytes, the strengthened regulatory activity of CD4⁺ Tregs through GALECTIN, and the exhaustion signatures in CD8⁺ T cells and mature NK c2 together form a coherent picture of an immune environment that may blunt the body’s ability to clear Mycobacterium tuberculosis during treatment. If these findings are confirmed in larger studies, the identified cell types and pathways—IL-16, TRAIL, GALECTIN signaling, inhibitory receptors on NK cells and the non-classical monocyte signature—could serve as blood-based biomarkers to predict early treatment failure. They also suggest directions for host-directed therapies aimed at reversing immunosuppression, restoring cytotoxic effector function, and improving outcomes for patients who are currently at high risk of poor response to standard TB therapy.